Table 6 The association between IFN-γ and sustained virologic response in HCV subgroups (IL28B_rs8099917 genotype TT vs. GT).

From: Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C

IFN-γ (pg/ml)

IL28B_rs 8099917 TT

IL28B_rs 8099917 GT

SVR

Non-SVR

X2 or Fisher’s

Odds ratio

SVR

Non-SVR

X2 or Fisher’s

Odds ratio

(n = 51)

(n = 11)

p-value

OR (95% C.I)

(n = 9)

(n = 4)

p-value

OR (95% C.I)

IFN-γ 4wk

 <180

44 (86.3%)

7 (13.7%)

0.094

1.36(0.86~2.15)

9 (81.8%)

2(18.2%)

0.077

–

 ≧180

7 (63.6%)

4 (36.4%)

  

0 (0.0%)

2(100.0%)

  

IFN-γ 12wk

 <120

39 (90.7%)

4 (9.30%)

0.026

1.44(1.01~2.05)

5 (83.3%)

1 (16.7%)

0.559

1.46(0.70~3.04)

 ≧120

12 (63.2%)

7 (36.8%)

  

4 (57.1%)

3 (42.9%)

  

IFN-γ EOT

 <40

39 (90.7%)

4 (9.30%)

0.026

1.44 (1.01~2.05)

6 (85.7%)

1 (14.3%)

0.266

1.71(0.73~4.03)

 ≧40

12 (63.2%)

7 (36.8%)

  

3 (50.0%)

3(50.0%)

  
  1. p.s. EOT: end of treatment.
Back to article page